Stockscreener 앱 받기
79.31
0.86%
-0.69
전일 마감가:
$80.00
열려 있는:
$80
하루 거래량:
63,363
Relative Volume:
0.37
시가총액:
$776.22M
수익:
-
순이익/손실:
$-4.98M
주가수익비율:
-60.19
EPS:
-1.3177
순현금흐름:
$-3.85M
1주 성능:
-11.88%
1개월 성능:
+4.36%
6개월 성능:
+80.46%
1년 성능:
+146.08%
1일 변동 폭
$79.26
$81.05
1주일 범위
$78.58
$90.95
52주 변동 폭
$23.18
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Compare DRUG vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
79.31 | 782.97M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-08 | 개시 | BTIG Research | Buy |
| 2025-05-13 | 개시 | TD Cowen | Buy |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-01-23 | 개시 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | Robert W. Baird | Outperform |
모두보기
Bright Minds Biosciences Inc 주식(DRUG)의 최신 뉴스
Bright Minds stock price target raised to $145 by H.C. Wainwright on trial data - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
DRUG: HC Wainwright & Co. Raises Price Target to $145, Maintains Buy Rating | DRUG Stock News - GuruFocus
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Precision Trading with Bright Minds Biosciences Inc. (DRUG) Risk Zones - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
DRUG Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bright Minds Biosciences to Present at Upcoming Conferences - Bitget
Published on: 2026-02-24 23:01:51 - baoquankhu1.vn
Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap UpWhat's Next? - MarketBeat
Stock Report: What are Bright Minds Biosciences Incs recent SEC filings showingJuly 2025 Chart Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Baird lowers Bright Minds Biosciences Inc. (DRUG) price target to $126, maintains outperform rating ahead of upcoming trials - MSN
Technical Reactions to DRUG Trends in Macro Strategies - Stock Traders Daily
Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials - Finviz
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Up 7.9%Here's What Happened - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from BTIG Research - MarketBeat
Will Bright Minds Biosciences Inc. benefit from rate cutsWeekly Trading Summary & AI Based Trade Execution Alerts - mfd.ru
7 Most Promising Psychedelic Stocks According to Hedge Funds - Insider Monkey
What are Bright Minds Biosciences Inc.’s recent SEC filings showingRate Cut & Weekly Top Gainers Trade List - mfd.ru
Wall Street Zen Upgrades Bright Minds Biosciences (NASDAQ:DRUG) to Hold - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Down 6.2%Time to Sell? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Issues Earnings Results, Beats Estimates By $0.28 EPS - MarketBeat
Bright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D Loss - TipRanks
Is Bright Minds Biosciences Inc. stock dividend yield sustainableJuly 2025 Trends & Free Community Supported Trade Ideas - mfd.ru
Will Bright Minds Biosciences Inc. benefit from rising consumer demandQuarterly Growth Report & Fast Moving Stock Watchlists - mfd.ru
Trading the Move, Not the Narrative: (DRUG) Edition - Stock Traders Daily
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Bright Minds Biosciences (DRUG) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Rally Mode: Is Bright Minds Biosciences Inc undervalued by DCF analysisJuly 2025 Technicals & AI Powered Market Entry Ideas - baoquankhu1.vn
Dow Update: Will Bright Minds Biosciences Inc. benefit from AI trendsWeekly Profit Recap & High Yield Equity Trading Tips - baoquankhu1.vn
How interest rate cuts could boost Bright Minds Biosciences Inc. stockJuly 2025 Sector Moves & Weekly Setup with ROI Potential - mfd.ru
Short Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Rises By 67.5% - MarketBeat
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet - MSN
What are the risks of holding Olin CorporationJuly 2025 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Several Bright Minds Biosciences Insiders Sell Shares Sending Potential Negative Signal - simplywall.st
Aug Big Picture: Is SSNC stock trending bullishJuly 2025 Big Picture & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
(DRUG) Volatility Zones as Tactical Triggers - Stock Traders Daily
Price-Driven Insight from (DRUG) for Rule-Based Strategy - Stock Traders Daily
Bright Minds reports positive Phase 2 results for epilepsy drug By Investing.com - Investing.com Nigeria
New epilepsy study tests drug for adults whose seizures resist treatment - Stock Titan
Volume Summary: How Bright Minds Biosciences Inc. stock performs in high volatility markets - Bộ Nội Vụ
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Bright Minds Biosciences Stock Topped the Market on Monday - MSN
Bright Minds Biosciences closes $175 million public offering By Investing.com - Investing.com Nigeria
Warm welcome for Aktis could open up IPO queue: Public Equity Report - BioCentury
Bright Minds Biosciences (NASDAQ:DRUG) Cut to "Sell" at Wall Street Zen - MarketBeat
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline - TipRanks
Bright Minds prices $175M stock offering - MSN
Bright Minds Biosciences Reports Phase 2 BMB-101 Data: 73% Median Drop in Absence Seizures on EEG - MarketBeat
Bright Minds Biosciences Closes its US$175 Million Public Offering - marketscreener.com
Bright Minds Biosciences Inc (DRUG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):